Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05559060
Collaborator
(none)
165
9
Study Details
Study Description
Brief Summary
Epilepsy is the second commonest chronic neurological disorder in developed countries ,comorbidity refers to the co-occurrence of two conditions with greater frequency than found in the general population
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational [Patient Registry]
Anticipated Enrollment
:
165 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Anticipated Study Start Date
:
Sep 1, 2022
Anticipated Primary Completion Date
:
May 1, 2023
Anticipated Study Completion Date
:
Jun 1, 2023
Outcome Measures
Primary Outcome Measures
- Find out comorbidities of epilesy and its treatment [1 year]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 65 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
Patients with primary epilepsy. Aged above 18 years old.
Exclusion Criteria:
- patient diagnosed as secondary epilepsy or epilepsy syndromes
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Hasnaa Abdallah,
Resident doctor,
Assiut University
ClinicalTrials.gov Identifier:
NCT05559060
Other Study ID Numbers:
- Comrbidities of epilepsy
First Posted:
Sep 29, 2022
Last Update Posted:
Sep 29, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: